112 related articles for article (PubMed ID: 2506003)
1. Suppression of serum immunoreactive human epidermal growth factor by acute increase in prolactin in women.
Chen CF; Kurachi H; Miyake A; Aono T; Tanizawa O
Endocrinol Jpn; 1989 Apr; 36(2):203-9. PubMed ID: 2506003
[TBL] [Abstract][Full Text] [Related]
2. Responses of growth hormone to metoclopramide in normal women and amenorrheic women with or without hyperprolactinemia.
Seki K; Kato K
Endocrinol Jpn; 1986 Oct; 33(5):721-5. PubMed ID: 3830074
[TBL] [Abstract][Full Text] [Related]
3. Increased thyroid-stimulating hormone response to thyrotropin-releasing hormone in hyperprolactinemic women.
Seki K; Kato K
J Clin Endocrinol Metab; 1985 Dec; 61(6):1138-41. PubMed ID: 3932450
[TBL] [Abstract][Full Text] [Related]
4. Serum prolactin response to thyrotropin-releasing hormone and metoclopramide in patients with prolactin-secreting tumors before and after transsphenoidal surgery.
Barbarino A; De Marinis L; Maira G; Menini E; Anile C
J Clin Endocrinol Metab; 1978 Nov; 47(5):1148-51. PubMed ID: 122421
[TBL] [Abstract][Full Text] [Related]
5. Catecholamines and pituitary function. III. Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia.
Nicoletti I; Filipponi P; Fedeli L; Sfrappini M; Gregorini G; Ambrosi F; Santeusanio F
Horm Res; 1984; 20(3):202-12. PubMed ID: 6436160
[TBL] [Abstract][Full Text] [Related]
6. Subnormal prolactin responsiveness to thyrotropin-releasing hormone (TRH) in women with primary empty sella syndrome.
Celani MF; Giambuzzi G; Simoni M; Montanini V
J Endocrinol Invest; 1987 Aug; 10(4):421-5. PubMed ID: 3119699
[TBL] [Abstract][Full Text] [Related]
7. Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity.
Bussen S; Brosemann N; Steck T
Gynecol Endocrinol; 1996 Apr; 10(2):83-90. PubMed ID: 8701791
[TBL] [Abstract][Full Text] [Related]
8. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects.
Anderson PW; Malarkey WB; Salk J; Kletsky OA; Hsueh WA
J Clin Endocrinol Metab; 1989 Sep; 69(3):518-22. PubMed ID: 2503532
[TBL] [Abstract][Full Text] [Related]
9. Functional evaluation of the adenohypophysis with metoclopramide in hyperprolactinemic-amenorrheic women in relation to radiological findings on the sella turcica.
Seki K; Uesato T; Kato K; Shima K
Endocrinol Jpn; 1984 Dec; 31(6):733-9. PubMed ID: 6532792
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of thyrotropin releasing hormone test in 129 patients with suspected tumoral hyperprolactinemia.
Smircić-Duvnjak L; Vizner B; Korsić M; Sekso M; Berković M
Coll Antropol; 2002 Dec; 26(2):635-40. PubMed ID: 12528293
[TBL] [Abstract][Full Text] [Related]
11. Changes in pituitary hormones during and following transsphenoidal removal of prolactinomas.
Casper RF; Rakoff JS; Quigley ME; Gilliland B; Alksne J; Yen SS
Am J Obstet Gynecol; 1980 Feb; 136(4):518-23. PubMed ID: 6766667
[TBL] [Abstract][Full Text] [Related]
12. Prolactin and thyrotropin responses to thyrotropin-releasing hormone in patients with secondary amenorrhea: the effect of bromocriptine.
Hirvonen E; Ranta T; Seppäla M
J Clin Endocrinol Metab; 1976 Jun; 42(6):1024-30. PubMed ID: 819453
[TBL] [Abstract][Full Text] [Related]
13. [Primary hyperprolactinemic amenorrhea. Report of 4 patients].
Rudolf K; Smid I; Kunkel S; Bazsa-Kassai Z
Zentralbl Gynakol; 1985; 107(14):894-8. PubMed ID: 3929499
[TBL] [Abstract][Full Text] [Related]
14. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
Barbarino A; de Marinis L; Menini E; Anile C; Maira G
Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
[TBL] [Abstract][Full Text] [Related]
15. Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects.
Camanni F; Genazzani AR; Massara F; La Rosa R; Cocchi D; Müller EE
Neuroendocrinology; 1980; 30(1):2-6. PubMed ID: 7354887
[TBL] [Abstract][Full Text] [Related]
16. Role of specific protein kinase C isozymes in mediating epidermal growth factor, thyrotropin-releasing hormone, and phorbol ester regulation of the rat prolactin promoter in GH4/GH4C1 pituitary cells.
Pickett CA; Manning N; Akita Y; Gutierrez-Hartmann A
Mol Endocrinol; 2002 Dec; 16(12):2840-52. PubMed ID: 12456804
[TBL] [Abstract][Full Text] [Related]
17. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M; Yamaji T
J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
[TBL] [Abstract][Full Text] [Related]
18. Prolactin responsiveness to TRH in amenorrheic women with and without galactorrhea.
MacGregor C; Maldonado D; Canales ES; Soria J; Zárate A
Acta Obstet Gynecol Scand; 1977; 56(4):333-6. PubMed ID: 414510
[TBL] [Abstract][Full Text] [Related]
19. PRL as a novel potent cofactor for platelet aggregation.
Wallaschofski H; Donné M; Eigenthaler M; Hentschel B; Faber R; Stepan H; Koksch M; Lohmann T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5912-9. PubMed ID: 11739463
[TBL] [Abstract][Full Text] [Related]
20. The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.
Prescott RW; Johnston DG; Taylor PK; Haigh J; Weightman DR; Hall K; Cook DB
J Endocrinol Invest; 1985 Feb; 8(1):49-54. PubMed ID: 3921596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
